NovoCure Ltd — Form 10-Q
Filed July 23, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Frank Leonard (CEO) and Christoph Brackmann (CFO) filed standard Sarbanes-Oxley certifications on July 23, 2026 for the quarter ended June 30, 2026. Both officers certify that the 10-Q contains no untrue material statements, that financial statements fairly present the company's condition and operations, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, significant deficiencies, or fraud are disclosed.
Why this rating
Routine SOX 302/906 certifications; boilerplate attestations with no substance changes, red flags, or business developments disclosed.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.